CRISPR/Cas9 targeting liposomes knocked down multidrug resistance proteins in brain endothelial cells as a model to predict potential pharmacoresistance

Yang, Tianzhi; Curtis, Skye; Bai, Albert; Young, Abby; Derosier, Derek; Ripley, Shannon; Bai, Shuhua

doi:10.1016/j.colsurfb.2022.113103

Cited by 10 publications

(7 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This model could be used to study efflux-mediated drug resistance. [93] Mechanism of SORT-LNPs: Selective organ targeting lipid nanoparticles (SORT-LNPs), reported for organ-specific nucleic acid (mRNA, CRISPR/Cas9 RNPs) delivery, were developed by augmenting the content of different lipids in a conventional Figure 6. a) A modular approach was developed to enable systemic nanoparticle delivery of CRISPR-Cas9 RNPs for tissue-specific genome editing.…”

Section: In Vivo Gene Editing Process and Mechanism Through Lnps/nano...mentioning

confidence: 99%

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective

et al. 2023

View full text Add to dashboard Cite

Clustered randomly interspaced short palindromic repeats (CRISPRs) and its associated endonuclease protein, i.e., Cas9, have been discovered as an immune system in bacteria and archaea; nevertheless, they are now being adopted as mainstream biotechnological/molecular scissors that can modulate ample genetic and nongenetic diseases via insertion/deletion, epigenome editing, messenger RNA editing, CRISPR interference, etc. Many Food and Drug Administration‐approved and ongoing clinical trials on CRISPR adopt ex vivo strategies, wherein the gene editing is performed ex vivo, followed by reimplantation to the patients. However, the in vivo delivery of the CRISPR components is still under preclinical surveillance. This review has summarized the nonviral nanodelivery strategies for gene editing using CRISPR/Cas9 and its recent advancements, strategic points of view, challenges, and future aspects for tissue‐specific in vivo delivery of CRISPR/Cas9 components using nanomaterials.

show abstract

Section: In Vivo Gene Editing Process and Mechanism Through Lnps/nano...mentioning

confidence: 99%

CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective

et al. 2023

View full text Add to dashboard Cite

show abstract

“…30 Furthermore, reversal of multidrug resistance (MDR) in brain cancer cells has also been made possible by the application of a CRISPR/Cas9 targeting the P-glycoprotein liposome in a recent investigation. 31 Recently, the codelivery of chitosan (CS) and hyaluronic acid conjugated triptorelin [which is a luteinizing hormone releasing hormone (LHRH)]…”

Section: Nanovectors For Crispr/cas9-based Cancer Treatmentmentioning

confidence: 99%

“…Recently, a DNA-mediated nanoframework has been employed for the codelivery of Cas9 ribonucleoprotein (RNP) along with antisense oligodeoxynucleotide (ASO) for the two-way cancer therapy . Furthermore, reversal of multidrug resistance (MDR) in brain cancer cells has also been made possible by the application of a CRISPR/Cas9 targeting the P-glycoprotein liposome in a recent investigation . Recently, the codelivery of chitosan (CS) and hyaluronic acid conjugated triptorelin [which is a luteinizing hormone releasing hormone (LHRH)] (HA-LHRH) along with CRISPR/Cas9 plasmid (CS/HA-LHRH/pCRISPR) has resulted in successful targeting of MCF-7 breast cancer cell lines by the downregulation of the ERCC1 gene (Figure ).…”

Section: Nanovectors For Crispr/cas9-based Cancer Treatmentmentioning

confidence: 99%

Advancing Era and Rising Concerns in Nanotechnology-Based Cancer Treatment

Tiwari,

Gupta,

Verma

et al. 2024

ACS Chem. Health Saf.

View full text Add to dashboard Cite

Cancer is one of the most prevalent causes of mortality worldwide. The arena of cancer diagnosis and therapy has undergone a tremendous revolution since the development of nanotechnology. Due to their nanosize and biocompatibility, nanoparticles are extensively employed for gene therapy and targeted drug delivery. Nanotechnology-based approaches have also shown promising advancements in the utilization of extracellular vesicles for cancer diagnosis, prognosis, and therapy. Apart from this, the CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9)-based nanotherapy and the development of therapeutic nanovaccines have also demonstrated encouraging results in revolutionizing cancer treatment. Nanotechnology-based molecular imaging and contrast agents can detect cancer at very early stages, allowing for prompt treatment and better patient outcomes. Although nanoparticles offer multiple benefits for drug administration, they additionally possess certain pharmacokinetic limitations, such as body clearance, restricted tissue penetration, confrontation with biological barriers, biodistribution, and accumulation. However, improvements in nanoparticle design are intended to resolve safety issues and enhance the therapeutic effects of these particles in a variety of disease complications. While nanotechnology has demonstrated immense potential in the treatment and diagnosis of cancer, there are still several challenges to overcome, including guaranteeing the safety of nanomaterials, taking into account regulatory issues, and creating scalable and affordable solutions. Nevertheless, new developments in nanotechnology and current research hold promise for further revolutionizing cancer detection and treatment.

show abstract

“…The sequence's formal name, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), was given in 2002 [8]. In 2010 and 2011, it was reported for the first time as a programmable system for the generation of DNA cleavage at the desired site in prokaryotes [9]. Shortly thereafter, researchers described the adaptability of the system to enable its use in eukaryotic cells [9].…”

Section: History Of Crispr-casmentioning

confidence: 99%

“…In 2010 and 2011, it was reported for the first time as a programmable system for the generation of DNA cleavage at the desired site in prokaryotes [9]. Shortly thereafter, researchers described the adaptability of the system to enable its use in eukaryotic cells [9]. In the year 2019, prime editing took genome editing to a new level by allowing the introduction of all types of mutations, including insertions, deletions and 12 base-to-base transitions [7].…”

Section: History Of Crispr-casmentioning

confidence: 99%